March 21st 2023
A genetic analysis indicates that multi-ancestry polygenic risk scores may be “potentially useful” in detecting risk of aggressive prostate cancer in patients of African ancestry, according to an expert from the University of Southern California.
March 14th 2023
Treatment Options in Metastatic Castration-Sensitive Prostate CancerMarch 13th 2022
In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.
Efstathiou Discusses Impact of Niraparib Combo From MAGNITUDE in mCRPCMarch 2nd 2022
Eleni Efstathiou, MD, PhD, spoke about how results of the phase 3 MAGNITUDE trial, which examined the combination of niraparib with abiraterone acetate and prednisone, have the ability to change the standard of care in patients with metastatic castration-resistant prostate cancer.
Efstathiou Discusses Positive Outcomes in HRR+ mCRPC With Niraparib Combo in MAGNITUDE TrialFebruary 25th 2022
Eleni Efstathiou, MD, PhD, spoke about the positive results seen in the phase 3 MAGNITUDE trial in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations who were treated with a niraparib-containing regimen.
Enzalutamide Associated with Worsened Cognitive/Physical Function but Not Overall HQL in mHSPCFebruary 24th 2022
A health-related quality of life assessment found an association between worsened self-reported fatigue, cognitive function, and physical function, with enzalutamide treatment for patients with metastatic, hormone-sensitive prostate cancer but improved deterioration-free survival for overall health and quality of life.
Merseburger Offers PRESIDE Trial Overview of Continuous Enzalutamide in mCRPCFebruary 23rd 2022
Axel Merseburger, MD, PhD, spoke key results of the PRESIDE trial, which examined continuous enzalutamide to treat patients with metastatic castration-resistant prostate cancer and progressive disease.
PROpel Trial Data Show Boost in Radiographic PFS With Olaparib/Abiraterone for mCRPCFebruary 19th 2022
Results of the phase 3 PROpel trial presented at 2022 ASCO GU indicate a benefit of olaparib-based therapy for patients with metastatic castration-resistant prostate cancer receiving treatment in the frontline setting.
Favorable Detection Rates Reported With 18F-rhPSMA-7.3 for Recurrence of Prostate CancerFebruary 18th 2022
Data reported from the phase 3 SPOTLIGHT trial of the novel theranostic 18F-rhPSMA-7.3 at 2022 ASCO GU show “excellent image quality” for prostate cancer recurrence detection, according to expert.
Metastatic CRPC With Alterations in Homologous Recombination Repair Genes Benefits From Frontline NiraparibFebruary 18th 2022
Data presented at 2022 ASCO GU of niraparib-based therapy for patients with metastatic castration-resistant prostate cancer showed a boost in radiographic progression-free survival vs matched placebo.
PRESIDE Trial Meets Primary End Point With Continuous Enzalutamide After Progression of mCRPCFebruary 18th 2022
The phase 3b PRESIDE trial showed significant progression-free survival improvement when men with chemotherapy-naïve metastatic castration-resistant prostate cancer were treated with a regimen of continuous enzalutamide vs placebo.
Patients With nmCRPC Continue to See Benefit With Darolutamide Despite Comorbidities, Concomitant MedicationsFebruary 17th 2022
Data from the ARAMIS trial that were presented at 2022 ASCO GU showed that darolutamide benefit for patients with nonmetastatic castration-resistant prostate cancer was consistent regardless of the number of comorbidities or concomitant medications.
Efstathiou Discusses Background of Niraparib Combo in HHR-Altered mCRPC From MAGNITUDE TrialFebruary 17th 2022
Eleni Efstathiou, MD, PhD, spoke about the treatment combination of niraparib plus abiraterone acetate and prednisone for the treatmeant of men with metastatic castration-resistant prostate cancer in the phase 3 MAGNITUDE trial.
FDA Grants Breakthrough Device Designation to Blood Test for Detecting Early-Stage Prostate CancerFebruary 17th 2022
Datar Cancer Genetics announced that its TriNetra-Prostate blood test, which was developed to detect early-stage prostate cancer, received breakthrough device designation from the FDA.
Recap: Recent Advances in the Treatment of Metastatic Prostate CancerJanuary 30th 2022
Experts in prostate cancer discuss recent advances in the treatment of patients with metastatic castration-naive and metastatic castration-resistant prostate cancer and strategies for optimizing therapy.
Meta-Analysis Indicates Black Individuals With Prostate Cancer May Have Better Outcomes in Radiation Therapy Clinical Trials vs White PatientsJanuary 14th 2022
Despite presenting with high-risk disease, Black patients with prostate cancer who enrolled on radiation therapy clinical trials were reported to have better rates of biochemical recurrence, distant metastases, and prostate cancer–specific mortality than White patients.
Abiraterone/ADT Combo Associated With High Metastasis-Free Survival Rate in Non-Metastatic Prostate CancerJanuary 10th 2022
A meta-analysis of 2 phase 3 randomized trials found that combination therapy including androgen deprivation therapy led to higher rates of metastasis-free survival for patients with high-risk non-metastatic prostate cancer.